ArticlePediatrics2025
Human Metapneumovirus and Respiratory Syncytial Virus in Children: A Comparative Analysis.
Article in Pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Clinical Features and Predictors of Severity in Children Hospitalized With Human Metapneumovirus: A Multicenter Italian Study.The Pediatric infectious disease journal · 2026Observational
- Genomic Surveillance of Human Metapneumovirus in the United States, 2010-2025.The Journal of infectious diseases · 2026Article
- Twenty-five years of human metapneumovirus research.Clinical microbiology reviews · 2026Review
- Human Metapneumovirus-Associated Hospitalization Burden in Children Aged Under 5 Years in Scotland Between 2017 and 2023: a Retrospective Analysis.Open forum infectious diseases · 2026Article
- Comparison of the Hospital Burden Associated with Respiratory Syncytial Virus and Human Metapneumovirus Across All Age Groups in Scotland: A Retrospective Analysis.Infectious diseases and therapy · 2026Article
- Live human metapneumovirus vaccine candidates attenuated by temperature sensitivity mutations from human respiratory syncytial virus.Journal of virology · 2026Article
- Comparison of human metapneumovirus and respiratory syncytial virus in children with acute lower respiratory infections in Wenzhou, China from 2021 to 2022: a retrospective study.BMC pediatrics · 2026Article
- Respiratory viral infections in children under five during two consecutive autumn-winter seasons.BMC infectious diseases · 2026Observational
- Associations of age, comorbidities, and inflammatory markers with disease severity in pediatric human metapneumovirus infection.European journal of pediatrics · 2026Article
- Comparison of Healthcare Resource Utilization and Disease Outcomes in Adults Hospitalized with Human Metapneumovirus and Respiratory Syncytial Virus.The Journal of infectious diseases · 2026Article
- Article
- Genomic surveillance of human metapneumovirus in the United States, 2010 - 2025.medRxiv : the preprint server for health sciences · 2026Article
- Human metapneumovirus prevention in children: emerging roles of monoclonal antibodies and vaccines.Frontiers in immunology · 2026Review
- Clinical efficacy of immunoglobulin in pediatric patients with severe respiratory syncytial virus pneumonia: a retrospective clinical analysis.Frontiers in medicine · 2026Article
- Human Metapneumovirus: A Narrative Review on Emerging Strategies for Prevention and Treatment.Viruses · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundHuman metapneumovirus (HMPV) and respiratory syncytial virus (RSV) are genetically related viruses and major causes of medically attended acute respiratory illness in children. Research comparing the severity of illnesses resulting from these infections lacks consensus.
methodsChildren younger than 18 years with acute respiratory illness were enrolled through active, prospective surveillance from 2016 to 2020 at 7 US pediatric hospitals and emergency departments (EDs). Clinical information was obtained from parent interviews and medical records. Midturbinate nasal swabs were collected and tested for RSV and HMPV using molecular diagnostic assays at each site. We compared descriptive and clinical features of children with RSV or HMPV and calculated adjusted odds ratios (aOR) for severe outcomes comparing RSV with HMPV. Risk factors for severe outcomes were assessed in children with RSV or HMPV using logistic regression models.
resultsA total of 5329 children hospitalized with RSV (n = 4398) or HMPV (n = 931) and 3276 children with RSV-associated (n = 2371) or HMPV-associated (n = 905) ED visits were enrolled. The median age of children hospitalized with RSV was lower than that of children with HMPV (7 months vs 16 months, P < .0001). Children presenting to the ED with RSV-associated acute respiratory illness had higher odds of being hospitalized than children with HMPV (aOR, 1.68; 95% CI, 1.50-1.87), with the highest odds in infants younger than 6 months (aOR, 3.27; 95% CI, 2.53-4.23). Underlying conditions were more than twice as common among infants hospitalized with HMPV (26%) than those with RSV (11%).
conclusionsChildren with HMPV-associated hospitalization tend to be older and more likely to have underlying medical conditions compared with children with RSV-associated hospitalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.